LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease

Our Bureau

LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative cell therapy transplanted into patients’ lymph nodes as a potential treatment for end-stage liver disease (ESLD). “In […]

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Our Bureau

Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.  During a typical anaesthetic procedure, less than five percent of the volatile […]

Join Els for Autism® in Celebrating World Autism Month: Creating Opportunities for Inclusion and Acceptance of Individuals with Autism Spectrum Disorder

Our Bureau

As we prepare to celebrate World Autism Month this April, Els for Autism invites individuals and families to join us in our mission of creating a world of limitless possibilities for individuals with autism spectrum disorder (ASD) and their families. Through our comprehensive programs and services spanning a lifetime, the Els for […]

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Our Bureau

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). […]

Subscribe Now